Bank of New York Mellon’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Bank of New York Mellon’s Portfolio KRSA Stock Details KRSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-475	Closed	-$74K	–	4609
2022 Q1	$74K	Sell	475 -2	-0.4%	-$48	﹤0.01%	4461
2021 Q4	$114K	Hold	477	–	–	﹤0.01%	4386
2021 Q3	$205K	Hold	477	–	–	﹤0.01%	4207
2021 Q2	$260K	Sell	477 -223	-32%	-$14K	﹤0.01%	4009
2021 Q1	$273K	Sell	700 -15	-2%	-$1.13K	﹤0.01%	3948
2020 Q4	$306K	Buy	715 +84	+13%	+$5.73K	﹤0.01%	3824
2020 Q3	$538K	Sell	631 -4	-0.6%	-$457	﹤0.01%	3456
2020 Q2	$526K	Sell	635 -52	-8%	-$4.35K	﹤0.01%	3443
2020 Q1	$255K	Sell	687 -1	-0.1%	-$71	﹤0.01%	3667
2019 Q4	$262K	Buy	688 +77	+13%	+$7.19K	﹤0.01%	3841
2019 Q3	$1.04M	Buy	611 +56	+10%	+$12.1K	﹤0.01%	3164
2019 Q2	$890K	Buy	+555	New	+$157K	﹤0.01%	3296

Other funds holding KRSA

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TFS

TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Bank of New York Mellon's KRSA Position: Q2 2022 in Review

Bank of New York Mellon sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q2 2022, closing a stake of 475 shares — an estimated $74K sold.

Bank of New York Mellon first reported a position in KRSA in Q2 2019 and held it in 12 quarters. The position peaked at $1.04M in Q3 2019. 36 funds tracked by Wall St. Rank hold KRSA as of Q2 2022.

Bank of New York Mellon reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Bank of New York Mellon sold 475 Korsana Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $74K.
Bank of New York Mellon first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
Bank of New York Mellon's Korsana Biosciences, Inc. Common Stock position peaked at $1.04M in Q3 2019.
36 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.